{
  "url": "https://struct.news/briefs/royalty-pharmas-operating-profit-jumped-32-its-earnings-barely-moved",
  "title": "Royalty Pharma’s operating profit jumped 32%. Its earnings barely moved",
  "summary": "Trelegy royalty receipts added $12.4 million, but cash fell 37.5% in the same three months.",
  "published_at": "2026-08-05T13:03:54.831433+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "Royalty Pharma plc",
    "ticker": "RPRX",
    "cik": "1802768",
    "sector": "Healthcare",
    "industry": "Biotechnology"
  },
  "source_filing": {
    "form": "10-Q",
    "filed": "2026-05-06",
    "accession": "0001802768-26-000009",
    "url": "https://www.sec.gov/Archives/edgar/data/1802768/000180276826000009/rprx-20260331.htm"
  },
  "comparison_filing": {
    "form": "10-Q",
    "filed": "2025-11-05",
    "url": "https://www.sec.gov/Archives/edgar/data/1802768/000180276825000114/rprx-20250930.htm"
  },
  "reported_figures": [
    {
      "group": "The filing in three numbers",
      "label": "Revenue",
      "value": 2378193000,
      "display": "$2.4B",
      "unit": "usd",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "sec_filing",
        "label": "Filed company results",
        "form": "10-Q",
        "accession": "0001802768-26-000009",
        "filing_date": "2026-05-06"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Revenue YoY",
      "value": 5.063536634069288,
      "display": "+5.1%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001802768-26-000009",
        "filing_date": "2026-05-06"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Operating margin",
      "value": 65.5757543647635,
      "display": "+65.6%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001802768-26-000009",
        "filing_date": "2026-05-06"
      }
    }
  ],
  "watch_next": [
    {
      "type": "partner_dependency",
      "statement": "Announced January 2026 funding agreement with Teva Pharmaceuticals for TEV-’408 for up to $500 million.",
      "importance": "high",
      "evidence": "In January 2026, we announced a funding agreement with Teva Pharmaceuticals for TEV-’408 for up to $500 million.",
      "source_date": "2026-05-06"
    }
  ],
  "related_tickers": [
    "RPRX"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}